Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 1

Status

Completed 5Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 2Thoracic 1Sarcoma 1

Conditions

Breast Neoplasms 38Neoplasm Metastasis 10Neoplasms 7Brain Neoplasms 4Triple Negative Breast Neoplasms 3HER2-positive Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Advanced Malignant Solid Tumors 3Stomach Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytosis 1Solid Tumor 1Salivary Gland Neoplasms 1Recurrence 1Rare Tumour 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neuroma, Acoustic 1Neurofibromatosis 2 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Neoplasms × neratinib × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01953926 2024-03-12

SUMMIT

Puma Biotechnology, Inc.

Phase 2 Terminated
582 enrolled 27 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT00838539 2018-09-18

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
63 enrolled 26 charts
Tumor-Agnostic

Neoplasms

NCT00146172 2018-09-17

Study Evaluating HKI-272 in Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
73 enrolled 20 charts
Breast

Breast Neoplasms, Neoplasms

NCT00397046 2018-09-14

A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
21 enrolled 13 charts
Tumor-Agnostic

Neoplasms

NCT00300781 2018-08-14

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Puma Biotechnology, Inc.

Phase 2 Completed
136 enrolled 11 charts
Breast

Breast Neoplasms, Neoplasms

NCT00445458 2018-07-26

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Puma Biotechnology, Inc.

Phase 1/2 Completed
110 enrolled 13 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡